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Abstract Ectopic expression of Bcr-Abl, Bcl-2 or Bcl-xL in
HL-60 cells conferred resistance to apoptosis against a variety
of death-inducing agents. Bcr-Abl-mediated interference with
mitochondrial events was con¢rmed by the analysis of the loss
of mitochondrial transmembrane potential and cytochrome c
release. HL-60.Bcr-Abl cells were extremely resistant to all
apoptogenic stimuli tested, even in circumstances where HL-
60.Bcl-2 or HL-60.Bcl-xL cells were only partially protected
from apoptosis. The levels of Mcl-1, Bax, Bid, Akt, c-IAP-1,
c-IAP-2, XIAP and c-FLIP were compared in all HL-60 lines.
Our ¢ndings show that Bcr-Abl is a more powerful anti-apopto-
tic molecule than Bcl-2 or Bcl-xL.
, 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Apoptosis is a form of cell death triggered during a variety
of physiological conditions and is dependent on the activation
of particular biochemical pathways inside the dying cells [1].
Once stress signals are initiated, apoptosis can still be halted
by the expression of anti-apoptotic molecules of the Bcl-2
family, which play their role at the mitochondrial level by
blocking the release of apoptogenic factors such as cyto-
chrome c, SMAC/Diablo and AIF [2,3]. Beyond this control
point, apoptosis is triggered by the activation of caspase-9 in a
multi-molecular complex called apoptosome, which is com-
posed of APAF-1, ATP, cytochrome c and pro-caspase-9 mol-
ecules. Afterwards, caspase-9 activates the executioner cas-
pases, such as caspase-3, -6 and -7. Although caspases are
the molecules responsible for the morphological and biochem-
ical changes associated with apoptosis, the control of the de-
cision between life and death relies on the mitochondria [4,5].
Another checking point where apoptosis can be inhibited is
the activation of caspases, which can be blocked by certain
endogenous inhibitors called IAPs (inhibitors of apoptosis).
IAPs were ¢rst identi¢ed in baculoviruses, where they act as
a molecular tool for preventing apoptosis in the host insect
cells, therefore boosting viral replication. They have multiple
biological activities and besides binding and inhibiting cas-
pases they can regulate cell cycle progression and modulate
receptor-mediated signal transduction [6,7].
Finally, molecules such as c-FLIP are able to interfere with
the apoptotic program initiated by the activation of death
receptors, by competing with the initiator caspases (caspase-
8 and -10) associated with the Fas receptor complex, shutting
o¡ the downstream Fas signaling pathway [8].
Bcr-Abl is a constitutively activated tyrosine kinase respon-
sible for the resistance to apoptosis observed in Philadelphia
chromosome-positive leukemia. It has been suggested that
Bcr-Abl operates at the mitochondrial level to prevent apo-
ptosis initiated by a variety of chemotherapeutic treatments
[9,10]. In fact, we have shown that Bcl-xL, but not Bcl-2,
mediates in part the anti-apoptotic e¡ect of Bcr-Abl [10],
although it was also proposed that Bcl-2 may play a role in
other experimental systems [11,12]. Recently, it was revealed
that Bcr-Abl regulates the transcription of bcl-xL through the
activation of STAT-5 [13]. In addition, anti-apoptotic signals
initiated by Bcr-Abl may also involve the phosphoinositide 3P-
kinase (PI3K)/Akt pathway [14], even though in our experi-
mental system inhibitors such as wortmannin do not interfere
with the strong resistance to apoptosis observed in HL-
60.Bcr-Abl cells, despite knocking down PI3K activity [15].
The aim of this work was to systematically compare the
outcome of ectopic expression of Bcr-Abl, Bcl-2 and Bcl-xL
on the resistance to apoptosis induced by a variety of trigger-
ing agents. We therefore used stable lines of transfected HL-
60 cells to investigate which step of the apoptotic machinery
was most in£uenced by each of these anti-apoptotic mole-
cules.
2. Materials and methods
2.1. Cells
Human acute myeloid leukemia HL-60 cells ectopically expressing
Bcr-Abl, Bcl-2 or Bcl-xL were previously described [9,10].
2.2. Reagents
The bacterial expression vector pProEX.annexin V was a generous
gift from Dr. Seamus J. Martin (Trinity College, Dublin, Ireland).
DiOC6 was purchased from Molecular Probes (Eugene, OR, USA).
Actinomycin D (Act-D), cytosine arabinoside (Ara-C), cycloheximide
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(CHX), etoposide (VP-16), nocodazole (Noco), staurosporine (STS)
and vincristine sulfate (VCS) were ordered from Sigma Chemicals (St.
Louis, MO, USA). Calphostin C (Cal-C) and camptothecin were from
Calbiochem (San Diego, CA, USA).
2.3. Antibodies
Antibodies were obtained from di¡erent sources. Anti-CD95 IgM
monoclonal antibody (mAb) (CH11) was purchased from Medical
and Biological Laboratories (Nagoya, Japan). Anti-XIAP mAb,
anti-caspase-3, anti-caspase-9, anti-Bax and anti-Bcl-xL polyclonal
antibodies (pAbs) (Pharmingen, San Diego, CA, USA), anti-c-IAP-1
and anti-Mcl-1 pAbs (Santa Cruz, Santa Cruz, CA, USA) anti-phos-
photyrosine mAb (Upstate Biotech, Lake Placid, NY, USA), anti-Akt
mAb (New England Biolabs, Beverly, MA, USA), anti-c-IAP-2 pAb
(RpD Systems, Minneapolis, MN, USA), anti-c-Abl mAb (Calbio-
chem, San Diego, CA, USA), anti-Bcl-2 mAb (Dako, Carpinteria,
CA, USA), anti-actin mAb (ICN, Costa Mesa, CA, USA), anti-mouse
IgG-horseradish peroxidase (HRP) and anti-rabbit Ig-HRP (Amer-
sham Pharmacia Biotech, Uppsala, Sweden) were used as suggested
by the manufacturers. Anti-caspase-8 mAb and anti-c-FLIP mAbs
were generously provided by Dr. Marcus Peter (University of Chica-
go, Chicago, IL, USA). Anti-Bid mAb was kindly provided by Dr.
Stanley Korsmeyer (Washington University, Seattle, WA, USA) and
anti-SMAC pAb was a generous gift from Dr. Seamus J. Martin
(Trinity College, Dublin, Ireland).
2.4. Production of recombinant annexin V-FITC
Recombinant His-tagged annexin V was produced using the
pProEX1 HT Prokaryotic Expression System (Life Technologies)
and puri¢ed in a HiTrap1 Chelating HP column (Amersham Bio-
sciences), according to the instruction of the manufacturer. Puri¢ed
His-annexin V was labeled with FITC (Sigma-Aldrich), following the
protocol provided with the product.
2.5. Determination of apoptosis
Apoptosis was assessed by several criteria. DNA fragmentation was
quanti¢ed by cell cycle analysis of total DNA content as described by
Nicoletti et al. [16]. The collapse of the inner mitochondrial trans-
membrane potential (vim) was measured using DiOC6 dye [17,18].
Quantitative determination and di¡erentiation of viable, early, and
late apoptotic cells were carried out using annexin V/propidium iodide
staining, as previously described [19]. All results represent the average
obtained in triplicate samples. The variations among the triplicates
were always less than 10%. Every experiment was repeated two to
three times.
2.6. SDS^PAGE and Western blot
Protein samples were resolved under reducing conditions as previ-
ously described [18,20]. For total cell lysates, cells were harvested,
washed once in ice-cold phosphate-bu¡ered saline (PBS), lysed di-
rectly in sodium dodecyl sulfate (SDS) sample bu¡er (50 mM Tris^
HCl, pH 6.8, 2% SDS, 10% glycerol, 2.5% 2-mercaptoethanol), and
boiled for 5 min. For preparation of cytosolic fractions, cells were
washed once with ice-cold PBS and permeabilized for 5 min on ice
at a density of 3U107/ml in cytosolic extraction bu¡er (250 mM
sucrose, 70 mM KCl, 137 mM NaCl, 4.3 mM Na2HPO4, 1.4 mM
KH2PO4, pH 7.2, 100 WM phenylmethylsulfonyl £uoride, 10 Wg/ml
leupeptin, 2 Wg/ml aprotinin, containing 250 Wg/ml digitonin). Samples
were then centrifuged at 1000Ug for 5 min at 4‡C, the supernatants
were collected and appropriately diluted with 5USDS^polyacrylamide
gel electrophoresis (PAGE) sample bu¡er. A total of 20^30 Wg of
protein was loaded per lane and Western blot reactions on polyvi-
nylidene di£uoride membranes were detected using enhanced chemi-
luminescence (ECL, Amersham, Arlington, IL, USA).
3. Results and discussion
3.1. Multi-drug resistance of HL-60 cells expressing
anti-apoptotic genes
Although Bcr-Abl has no structural homology with Bcl-2
members, it has been suggested that this oncogenic tyrosine
kinase blocks the apoptotic machinery at the mitochondrial
level [9,10], resembling therefore the function of anti-apopto-
tic members of the Bcl-2 family [21]. To gain insight into the
molecular basis that controls the resistance to apoptosis in-
duced by Bcr-Abl, we sought to verify whether the ectopic
expression of Bcr-Abl, Bcl-2 or Bcl-xL in HL-60 cells would
provide similar anti-apoptotic signals and consequently simi-
lar protection to a variety of apoptogenic insults.
Using the DNA fragmentation assay, we con¢rmed that the
stable expression of Bcr-Abl, Bcl-2 or Bcl-xL in HL-60 cells
converted this apoptosis-sensitive line into resistant cells (Ta-
ble 1). DNA-damaging agents (Ara-C, VP-16, teniposide,
camptothecin), protein kinase inhibitors (STS and Cal-C), cy-
toskeleton-disrupting drugs (VCS and Noco) and protein
(CHX) or RNA (Act-D) synthesis inhibitors were used as
the apoptogenic stimuli.
Interestingly, albeit resistant to apoptosis, HL-60.Bcr-Abl,
HL-60.Bcl-2 and HL-60.Bcl-xL cells were susceptible to
changes in the cell cycle imposed at least by some of the
drugs, such that surviving cells appear to be arrested in G2
after treatments with VCS, Noco (Fig. 1) and, to a lesser
extent, Cal-C (data not shown).
When we analyzed the results in more detail, we noticed
that the HL-60.Bcr-Abl cells were much more resistant than
HL-60.Bcl-2 or HL-60.Bcl-xL cells. In some cases, including
STS treatment, the resistance conferred by Bcr-Abl (85% of
cells alive) in comparison to Bcl-2 (44%) and Bcl-xL (46%) was
very impressive (Table 1). Such extreme protection could also
be seen after the incubation of cells with camptothecin, where
84% of Bcr-Abl cells were protected from apoptosis whereas
just 52% of Bcl-2 and 43% of Bcl-xL cells remained alive after
the treatment (Table 1). In both cases, only 2^4% of the HL-
60 vector control cells survived the incubation with these
drugs.
3.2. Externalization of phosphatidylserine residues
Since we looked at only one of the consequences of apo-
ptosis, and DNA fragmentation is rather a late event in the
apoptosis cascade, we decided to investigate whether phospha-
tidylserine (PS) externalization was also di¡erentially regu-
lated in HL-60 cells overexpressing Bcr-Abl, Bcl-2 and Bcl-
xL. It is well know that PS externalization happens early dur-
Table 1
Di¡erential resistance of HL-60 cells expressing anti-apoptotic genes
Control Teniposide VP16 Camptothecin Ara-C STS Cal-C CHX Act-D VCS Noco
HL-60.neo 5R 0.5 97R 2.0 91R 0.2 96R 0.2 60R 2.0 98R 0.4 91R1.0 39R 5.0 90R 3.0 70R 0.3 59R 12
HL-60.Bcr-Abl 7R 1.4 8R 0.1 7R 0.2 16R 0.7 9R 0.1 15R 0.1 8R1.5 10R 1.0 11R 0.2 10R 0.8 12R 1.5
HL-60.Bcl-2 4R 0.4 19R 0.1 34R 0.1 48R 0.5 20R 2.0 66R 0.9 18R4.0 21R 1.7 9R 1.4 26R 1.6 20R 2.3
HL-60.BclxL 4R 0.7 30R 1.3 38R 10 57R 6.0 32R 0.1 64R 1.0 8R0.7 13R 0.4 5R 0.2 28R 2.0 29R 7.0
HL-60, HL-60.Bcr-Abl, HL-60.Bcl-2 and HL-60.Bcl-xL were treated for 18 h with di¡erent death-inducing agents and apoptosis was estimated
by cell cycle analysis. Numbers represent the average percentageRS.D. of cells with sub-diploid DNA contents. Results show triplicate samples
from a representative of three independent experiments.
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ing apoptosis [19]. Moreover, from a biological point of view
this is perhaps the most important modi¢cation that occurs in
the apoptotic cells, as ‘PS £ip’ is the prominent ‘eat-me’ signal
recognized by macrophages in order to remove the dying cells
in the organism without initiating in£ammatory reactions [22^
24].
PS £ip occurred in HL-60 vector control cells after every
pro-apoptotic treatment tested, although with di¡erent inten-
sities (Fig. 2). HL-60.Bcl-2 and HL-60.Bcl-xL cells behaved
quite similarly regarding to their resistance to PS externaliza-
tion and HL-60.Bcr-Abl cells displayed the strongest resis-
tance to this apoptotic event, never showing PS £ip above
control levels (Fig. 2).
3.3. Mitochondrial changes during apoptosis
Most of the apoptogenic signaling pathways are regulated
by mitochondrial events such as the release of cytochrome c
and SMAC/Diablo to the cytosol, which is often accompanied
by the loss of mitochondrial transmembrane potential (vim).
It is well established in the literature that both Bcl-2 and Bcl-
xL operate in the apoptotic machinery by blocking cell death
at the mitochondrial level, therefore preventing the release of
Fig. 1. Changes in cell cycle of HL-60 cells expressing anti-apoptotic genes. HL-60 cell lines were treated with 100 WM VCS or 10 Wg/ml Noco
for 18 h and changes in cell cycle were determined by propidium iodide assay. Figure shows representative data of three independent experi-
ments.
Fig. 2. PS externalization after apoptogenic drugs. HL-60, HL-60.Bcr-Abl, HL-60.Bcl-2 and HL-60.Bcl-xL were treated for 18 h with di¡erent
death-inducing agents and apoptosis was estimated by the annexin V binding assay. Numbers represent the averageRS.D. Figure shows repre-
sentative data of three independent experiments.
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cytochrome c and the loss of vim [21]. In extreme situations
where the amount of these two molecules is not enough to
handle the apoptogenic stimuli, cytochrome c is released and
death occurs by a caspase-dependent mechanism. Hence, we
used four drugs with di¡erent modes of action to investigate
whether the release of cytochrome c and the loss of vim were
di¡erentially a¡ected by the expression of Bcr-Abl, Bcl-2 or
Bcl-xL.
Regarding the changes in vim, we observed that among the
lines analyzed, Bcr-Abl-expressing HL-60 cells were again in-
£uenced least by pro-apoptotic drugs (Fig. 3). Treatment with
STS, VP-16, CHX or VCS induced important losses of vim in
HL-60.neo cells (92%, 82%, 46%, 67%, respectively) and, to a
lesser extent, in HL-60.Bcl-2 (39%, 35%, 27%, 19%, respec-
tively) and HL-60.Bcl-xL (57%, 39%, 29%, 49%, respectively).
In contrast, HL-60.Bcr-Abl cells exhibited minimal changes in
vim (22%, 12%, 10%, 13%, respectively), implying that mito-
chondria from Bcr-Abl-positive cells were more resistant to
the deleterious e¡ect of the apoptogenic stimuli. In fact, this
presumption was corroborated by the fact that we could not
detect cytochrome c translocation from the mitochondria to
the cytosol in HL-60.Bcr-Abl cells after the same treatments
(Fig. 4 and data not shown). In comparison, only traces of
cytochrome c were detected in HL-60.Bcl-2 and HL-60.Bcl-xL
cells subjected to similar experimental conditions. As ex-
pected, every drug induced cytochrome c release in HL-
60.neo cells (Fig. 4 and data not shown).
To further con¢rm that the mitochondrial apoptotic path-
way is severely hindered in HL-60.Bcr-Abl cells we examined
the activation of caspases-9 and -3 after di¡erent apoptogenic
stimuli. As we can see, neither caspase-9 nor -3 was activated
after VP-16 (Fig. 5) or STS, CHX or VCS (data not shown).
We noticed that caspase-8 was activated after caspases-9 and
-3 in some circumstances, as a possible positive feedback
mechanism. On the other hand, caspase-2 was never activated
under our experimental conditions.
Interestingly, Bcr-Abl may also interfere with apoptosis up-
stream of mitochondria, since the activation of the Fas path-
way was blocked in HL-60.Bcr-Abl cells already at the level of
caspase-8 activation (Fig. 6A). In accordance with the litera-
Fig. 3. Loss of vim during apoptosis. HL-60 clones were treated for 18 h with di¡erent death-inducing agents and the collapse of vim was de-
termined by the DiOC6 assay. Numbers represent the averageRS.D. Figure shows representative data of two independent experiments.
Fig. 4. Cytochrome c release in HL-60 cells expressing anti-apoptotic genes. HL-60, HL-60.Bcr-Abl, HL-60.Bcl-2 and HL-60.Bcl-xL were
treated with 1 WM STS or 10 WM VP-16 for 4 h and cytosolic extracts were separated by SDS^PAGE and immunoblotted as described in Sec-
tion 2.
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ture, ectopic expression of Bcr-Abl, Bcl-2 or Bcl-xL conferred
resistance to apoptosis induced by anti-Fas antibodies (Fig.
6B).
3.4. Expression of regulators of apoptosis
We ¢nally compared the expression of some proteins impli-
cated in the regulation of apoptosis in the four cell lines used
in this study. Con¢rming our previous observation [10], while
HL-60 cells express Bcl-2 but not Bcl-xL, HL-60.Bcr-Abl cells
express Bcl-xL but not Bcl-2 (Fig. 7). As expected, the level of
Bcl-2 was higher in HL-60.Bcl-2 cells whereas the level of Bcl-
xL was greater in HL-60.Bcl-xL. The levels of the anti-apopto-
tic molecules Mcl-1 and the pro-apoptotic protein Bax were
similar in all four cell lines. In contrast, the expression of Bid
was considerably reduced in HL-60.Bcr-Abl cells, which may
therefore contribute to the resistance to apoptosis observed in
these cells. However, it is important to remark that Bid does
not play a role in every form of apoptosis. Thus, the reduced
level of this pro-apoptotic molecule in HL-60.Bcr-Abl cells
cannot entirely explain the outstanding resistance to apoptosis
conferred by the ectopic expression of Bcr-Abl in these cells.
We were not able to detect the expression of Bad in any of the
HL-60 lines. Due to the fact that HL-60 cells are feeble in Src
family kinases, the level of phosphotyrosine-containing pro-
teins in these cells is below the sensitivity of our Western blot
assay. Therefore, as predicted, phosphotyrosine-containing
proteins were found only in HL-60.Bcr-Abl cells. Actin was
used as an internal control for the immunoblots in order to
certify that the same amount of protein was loaded to the gels
in each sample.
The IAP family of proteins comprises caspase inhibitors
that were shown to have an evolutionarily conserved role in
Fig. 5. Caspases are not activated during apoptosis in HL-60 cells expressing anti-apoptotic genes. HL-60, HL-60.Bcr-Abl, HL-60.Bcl-2 and
HL-60.Bcl-xL were treated with 10 WM VP-16. Total cell lysates were obtained after di¡erent periods of time and proteins were analyzed by
Western blot using appropriate antibodies.
Fig. 6. Impaired caspase-8 activation and apoptosis in HL-60.Bcr-Abl cells treated with anti-Fas antibodies. HL-60 cell lines were incubated for
4 h (A) or overnight (B) in the presence or absence of 1 Wg/ml of anti-Fas antibody (CH11). Western blot analysis of caspase-8 activation (A)
and cell cycle analysis of genomic DNA content (B) were performed as described in Section 2.
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regulating apoptosis [6,7]. Ectopic expression of human IAP
proteins can suppress cell death induced by a variety of stim-
uli. We therefore investigated the levels of three members of
the IAP family, namely c-IAP-1, c-IAP-2 and XIAP, and
found that they are similar in all four lines investigated
(Fig. 7).
It was recently shown that the anti-apoptotic activity of the
IAPs can be obstructed by a mitochondrial molecule named
SMAC/Diablo, which is translocated to the cytosol during
apoptogenic stimulation [25,26]. Although we still do not
know whether Bcr-Abl controls the release of SMAC from
the mitochondria to the cytosol in a particular manner, we
detected similar amounts of this protein in all cell lines (Fig.
7).
The serine-threonine kinase Akt/PKB was shown to medi-
ate some of the anti-apoptotic activities of survival factors
such as platelet-derived and nerve growth factors and insu-
lin-like growth factor-1 [27]. This pathway is initiated by the
activation of PI3K after the engagement of survival factor
receptors and leads, among other biochemical modi¢cations,
to the phosphorylation of Bad, one of the pro-apoptotic mem-
bers of the Bcl-2 family [28]. Phosphorylated Bad binds to the
adapter protein 14-3-3 and remains sequestered in the cytosol.
When the survival signal ceases, Bad is dephosphorylated,
detaches from the 14-3-3 complex and migrates to the mito-
chondria where it will cause apoptosis. It has been suggested
that Bcr-Abl can activate the PI3K/Akt survival factor path-
way, which would consequently sustain the resistance to ap-
optosis in Bcr-Abl-positive cells [14]. Therefore, we looked at
the levels of Akt in the four HL-60 lines and found that they
are quite similar (Fig. 7). Although it is obvious that the
expression level of this protein does not necessarily correlate
with its activity, which may still be di¡erent in each of the
HL-60 lines, our previous data suggest that the PI3K/Akt
pathway is not activated by Bcr-Abl in HL-60.Bcr-Abl cells
and inhibitors of PI3K do not interfere with the resistance to
apoptosis found in these cells [15]. To ¢nally determine the
contribution of Akt to the resistance of HL-60.Bcr-Abl cells
we are at the moment generating an HL-60 cell line overex-
pressing an active form of Akt as well as an HL-60.Bcr-Abl
line that expresses a dominant negative form of Akt.
Another molecule with anti-apoptotic features is c-FLIP, a
protein homologous to the caspases but without their catalytic
activity [8]. c-FLIP seems to act by competing with caspase-8
to the Fas or other death receptor complexes. Interestingly,
the expression of c-FLIP long and short was slightly elevated
in HL-60.Bcr-Abl cells compared to the other cell lines (Fig.
7). Although we have not approached this question at the
moment, this result may be related to the observation that
caspase-8 was not activated in HL-60.Bcr-Abl cells after 4 h
incubation with anti-Fas antibodies (Fig. 6).
Knowing that apoptotic cell death is coordinated by certain
members of the caspases [1], we looked into the expression of
three di¡erent caspases. Our ¢ndings revealed that the levels
of caspases-8 and -3 were similar in all four cell lines (Fig. 7).
Surprisingly, HL-60.Bcr-Abl cells seem to express higher lev-
els of caspase-9.
To sum up, we found that the expression of Bcr-Abl in HL-
60 cells confers a condition of extreme resistance to apoptosis
regardless of the apoptogenic stimuli. Although the mitochon-
drial pathway is clearly involved in the forms of apoptosis
investigated in this study, the resistance of Bcr-Abl-positive
cells was stronger than the resistance observed after overex-
pression of Bcl-2 or Bcl-xL. In this regard, we found that
mitochondria from HL-60.Bcr-Abl cells were remarkably im-
mune to the deleterious e¡ect of the apoptogenic stimuli. In
addition, Bcr-Abl was capable of protecting HL-60 cells in
situations where Bcl-2 or Bcl-xL has no or very little e¡ect.
Fig. 7. Expression of proteins involved in apoptosis by HL-60 cells expressing anti-apoptotic genes. Total cell lysates of untreated HL-60, HL-
60.Bcr-Abl, HL-60.Bcl-2 and HL-60.Bcl-xL cells were analyzed by Western blot as described in Section 2.
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Finally, the expression of Mcl-1, Bad, Bax, c-IAP-1, c-IAP-2,
XIAP and Akt was similar in all HL-60 cell lines and, there-
fore, none of these molecules could be responsible for the
anti-apoptotic e¡ect of Bcr-Abl.
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